Rare ovarian tumours. Other treatments for ovarian cancer

• Published in: European journal of cancer supplements 2020-08, Vol.15, p.96-103
• Main Authors: Gil-Martin, Marta, Pardo, Beatriz, Barretina-Ginesta, Maria-Pilar
• Format: Article
• Language: English
• Subjects: Hormonotherapy; Rare malignant ovarian tumours; Targeted therapy
• ISSN: 1359-6349; 1878-1217
• DOI: 10.1016/j.ejcsup.2019.11.002

The description of rare malignant ovarian tumours and the most suitable treatments. Alternative therapies different from intravenous chemotherapy are also explained. Literature review and ongoing trial information have been used to elaborate this guide. Each ovarian cancer type must be identified and treated properly from diagnostic to surgery, adjuvant treatment and metastatic disease. Hormonotherapy can be useful as an alternative treatment, especially in low-grade ovarian cancer and endometrioid subtype. Tumour characterisation is appropriated for treatment selection when targeted therapy is indicated. MEK inhibitors, tyrosine-kinase inhibitors, EGFR inhibitors, therapies against integrins, antibody–drug conjugates and other strategies are described. Antiangiogenics, PARP inhibitors and immunotherapy are discussed in other parts of this publication. Different ovarian cancer types must receive the appropriated treatment. Alternative therapies may be evaluated beyond the standard therapy, frequently in a clinical trial, and an individualised molecular study may help to find the best treatment. •Rare Malignant Ovarian Tumors need a specific diagnosis and treatment.•Hormonotherapy is suitable for some ovarian cancers.•Molecular alterations analyses permits targeted therapy as a personalized medicine.